Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Morphosys Ag ADR (MOR)

Morphosys Ag ADR (MOR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,661,217
  • Shares Outstanding, K 126,336
  • Annual Sales, $ 90,280 K
  • Annual Income, $ -66,340 K
  • 60-Month Beta 0.99
  • Price/Sales 39.48
  • Price/Cash Flow N/A
  • Price/Book 6.68

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.38
  • Number of Estimates 2
  • High Estimate -0.33
  • Low Estimate -0.42
  • Prior Year -0.39
  • Growth Rate Est. (year over year) +2.56%

Price Performance

See More
Period Period Low Period High Performance
1-Month
25.81 +12.13%
on 10/29/19
29.50 -1.90%
on 11/18/19
+1.18 (+4.25%)
since 10/18/19
3-Month
25.81 +12.13%
on 10/29/19
31.71 -8.74%
on 08/21/19
-1.93 (-6.25%)
since 08/20/19
52-Week
22.46 +28.85%
on 03/28/19
31.96 -9.45%
on 08/08/19
+2.27 (+8.51%)
since 11/20/18

Most Recent Stories

More News
Markus Enzelberger, Chief Scientific Officer of MorphoSys, Announces His Departure

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 20, 2019 / MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) today announced that Dr. Markus Enzelberger, the company's Chief Scientific...

MOR : 28.94 (-0.14%)
Results for Bimagrumab in Obesity and Type 2 Diabetes Presented by MorphoSys's Partner

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 11, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) announced today that its licensee Novartis presented phase 2 results...

MOR : 28.94 (-0.14%)
NVS : 90.53 (+0.14%)
MorphoSys to Present Data on Tafasitamab at ASH 2019 Meeting

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 6, 2019 / MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) today announced presentation of so far unpublished data on tafasitamab,...

MOR : 28.94 (-0.14%)
MorphoSys AG Reports Third Quarter 2019 Financial Results

MorphoSys AG Reports Third Quarter 2019 Financial Results

MOR : 28.94 (-0.14%)
NVS : 90.53 (+0.14%)
MorphoSys AG: Ad hoc: Primary Endpoint Met in Real-World Data Study Demonstrating Clinical Superiority of the Combination of Tafasitamab and Lenalidomide Compared to Lenalidomide Alone

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / October 29, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; Nasdaq: MOR) today announced topline results from the primary analysis of the retrospective...

MOR : 28.94 (-0.14%)
MorphoSys AG: Primary Endpoint Met in Real-World Data Study Demonstrating Clinical Superiority of the Combination of Tafasitamab and Lenalidomide Compared to Lenalidomide Alone

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / October 29, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; Nasdaq: MOR):

MOR : 28.94 (-0.14%)
MOR106 Clinical Development in Atopic Dermatitis Stopped for Futility

MorphoSys AG (FSE:MOR; Prime Standard Segment, TecDAX; NASDAQ:MOR) today announced the end of the clinical development program of MOR106 in atopic dermatitis. The joint decision of all three involved parties,...

GLPG : 185.07 (+0.39%)
MOR : 28.94 (-0.14%)
NVS : 90.53 (+0.14%)
MorphoSys AG: MOR106 Clinical Development in Atopic Dermatitis Stopped

MOR106 Clinical Development in Atopic Dermatitis Stopped for futility

GLPG : 185.07 (+0.39%)
MOR : 28.94 (-0.14%)
MOR106 clinical development in atopic dermatitis stopped for futility

20.15 CET; regulated information - MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; NASDAQ: MOR) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced the end of the clinical development program...

GLPG : 185.07 (+0.39%)
MOR : 28.94 (-0.14%)
Invitation to MorphoSys Q3 2019 Conference Call on October 30, 2019

MorphoSys AG (FSE:MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ:MOR) will publish its first nine months' 2019 results on October 29, 2019 at 10:00pm CET (9:00pm GMT; 5:00pm EDT).

MOR : 28.94 (-0.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade MOR with:

Business Summary

MorphoSys AG is a biopharmaceutical company. It develops treatment for cancer, inflammations and autoimmune diseases. The company's proprietary portfolio consists of MOR208, MOR202, MOR103, MOR106 and MOR107. Its partnered programs lighthouse project includes Tremfya(R) and Gantenerumab. MorphoSys AG...

See More

Key Turning Points

2nd Resistance Point 29.59
1st Resistance Point 29.26
Last Price 28.94
1st Support Level 28.65
2nd Support Level 28.37

See More

52-Week High 31.96
Last Price 28.94
Fibonacci 61.8% 28.33
Fibonacci 50% 27.21
Fibonacci 38.2% 26.09
52-Week Low 22.46

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar